NeurologyLive® Friday 5 — February 27, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more buttons for more details and information about each highlight.

1: Examining Objective Concussion Monitoring in Collegiate Athletes

In this recent Q&A, Kyle Marden, MD, a sports neurologist at Northwestern Medicine, discussed the growing role of sports neurologists and new data supporting the feasibility of quantitative pupillometry as part of a multimodal approach to concussion diagnosis and recovery tracking.

2: Chronic Migraine Prevention in Diverse Populations: What the COMPEL Trial Reveals

In this recent Q&A, migraine expert Deena Kuruvilla, MD, FAAN, provided clinical context on the phase 4 COMPEL trial testing onabotulinumtoxinA as a preventive treatment of chronic migraine (CM) in diverse racial groups.

3: Translating Stem Cell Models Into Clinical Insights in Multiple Sclerosis: Valentina Fossati, PhD

In a recent interview at ACTRIMS Forum 2026, Valentina Fossati, PhD, a senior research investigator at the New York Stem Cell Foundation, answered questions about the research efforts needed to advance iPSC human models towards clinical relevance for patients with multiple sclerosis. [WATCH TIME: 4 minutes]

4: NeuroVoices: Shaliee Shah, MD, and Ditte Primdahl, MD, on Improving Diagnostic Accuracy in Paraneoplastic Neurologic Syndromes

In our latest NeuroVoices Q&A, neuro-oncologists Shailee Samir Shah, MD, and Ditte Primdahl, MD, both of Northwestern Medicine discussed how paraneoplastic neurologic syndromes differ from other cancer-related neurologic complications, highlighting key diagnostic challenges.

5: Testing Dual-Target Agent Loberamisal in Phase 3 Trial for Acute Ischemic Stroke: Shuya Li, MD

In a recent interview at ISC 2026, Shuya Li, MD, the head of the Phase I Clinical Research Unit at Beijing Tiantan Hospital, discussed positive clinical trial findings for a dual-target neuroprotectant in patients with acute ischemic stroke presented at ISC 2026. [WATCH TIME: 3 minutes]

Click here to view our latest video interview shorts with neurology experts.